Femasys (NASDAQ:FEMY) Rating Lowered to Sell at Wall Street Zen

Femasys (NASDAQ:FEMY) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other brokerages have also weighed in on FEMY. Maxim Group decreased their price objective on shares of Femasys to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. Lake Street Capital dropped their target price on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Finally, Weiss Ratings lowered shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Femasys Stock Performance

FEMY stock opened at $2.96 on Friday. Femasys has a twelve month low of $2.02 and a twelve month high of $22.20. The firm has a market cap of $24.80 million, a price-to-earnings ratio of -0.84 and a beta of -2.08. The business’s fifty day simple moving average is $3.36 and its two-hundred day simple moving average is $6.98. The company has a quick ratio of 0.55, a current ratio of 2.14 and a debt-to-equity ratio of 0.89.

Femasys (NASDAQ:FEMY) last issued its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The company had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.73 million. Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%.

Insiders Place Their Bets

In other news, CFO Dov Elefant purchased 15,625 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief financial officer owned 15,625 shares in the company, valued at approximately $50,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the acquisition, the chief executive officer directly owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 38,750 shares of company stock worth $124,000 in the last three months. Corporate insiders own 7.75% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Kovack Advisors Inc. purchased a new position in Femasys during the 4th quarter valued at about $27,000. HRT Financial LP purchased a new stake in shares of Femasys in the 4th quarter worth approximately $30,000. Cetera Investment Advisers purchased a new stake in shares of Femasys in the 4th quarter worth approximately $36,000. Osaic Holdings Inc. bought a new position in shares of Femasys during the second quarter valued at approximately $45,000. Finally, State Street Corp boosted its stake in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.